New cancer drug tested in patients with advanced tumors
NCT ID NCT05047536
Summary
This was a first-in-human study to test the safety and find the right dose of a new drug called KZR-261 for people with advanced solid tumors that had stopped responding to standard treatments. The trial enrolled 61 participants with cancers like melanoma, mesothelioma, colorectal cancer, and prostate cancer. The main goals were to see how the body processes the drug and to check for any serious side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED / METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
START (South Texas Accelerated Research Therapeutics)
San Antonio, Texas, 78229, United States
-
Sara Cannon Research Institution (SCRI) - Tennessee Oncology Nashville
Nashville, Tennessee, 37203, United States
-
University Hospitals - Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
Virginia Cancer Specialists (VCS)
Fairfax, Virginia, 22031, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.